LMDP10
LMDP10 is an orally active 3-amino quinazoline derivative with Keap1-Nrf2 pathway activation activity. LMDP10 binds to Keap1 to inhibit Keap1-Nrf2 interaction, thereby activating the Nrf2 pathway. LMDP10 elevates Nrf2, SOD, and GSH levels, reduces MDA and TNF-α levels, attenuates neurodegeneration, and improves memory function in Alzheimer’s disease (AD) rats. LMDP10 can be used for the study of AD[1].
Product Specifications
CAS Number
2760446-25-9
UNSPSC
12352005
Target
Drug Derivative; Keap1-Nrf2
Related Pathways
NF-κB; Others
Field of Research
Neurological Disease
Smiles
O=C(N(CC(N1NC(C2=CC=CC=C2)=O)=NC3=C(C=CC=C3)C1=O)C4=CC=C(F)C=C4)C5=CC=CC=C5
Molecular Formula
C29H21FN4O3
Molecular Weight
492.50
References & Citations
[1]Maheta P, et al. Neuroprotective Effects of a 3-Amino Quinazoline Derivative via Keap1-Nrf2 Pathway Activation in an ICV-STZ-Induced Rat Model of Sporadic Alzheimer's Disease. ACS Chem Neurosci. 2025 Sep 17;16 (18) :3611-3622.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
LY423568 100 µg
Atrophin 1 (ATN1) (NM_001007026) Human Over-expression Lysate
Sign In for Pricing
View Details 
